Camizestrant, Ribociclib, Azd9833
Er-Positive Her2-Negative Breast Cancer
Phase III
Recruiting
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
May 12, 2026
―
Belimumab
Bronchial Diseases
Phase III
Recruiting
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Nov 29, 2024
―
Mtx-463
Healthy
Phase I
Completed
A First-in-Human Safety Trial of MTX-463
Apr 22, 2024
―
H1 Influenza Antigen
Influenza
Phase I
Completed
Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP
Oct 30, 2023
―
Prx-102 1 Mg/Kg Every Two Weeks
Fabry Disease
Phase II/III
Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
Aug 10, 2023
―
Jcxh-105, Active Control
Infectious Disease, Herpes Zoster (Hz), Shingles
Phase I
Completed
A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine
May 03, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Icon plc (IJF) have in its pipeline
IJF is currently developing the following drugs: Camizestrant, Ribociclib, Azd9833, Anifrolumab, Jynneos, Mva-Bn. These drug candidates are in various stages of clinical development as the company works toward FDA approval.